Belcaro G, Legnini M, Cianchetti E, Errichi B M, Laurora G, Cipollone G, Leone L, Melena E, Lania M, Gaspari A L
Panminerva Med. 1989 Jan-Mar;31(1):34-41.
Defibrotide is a new compound with antithrombotic and profibrinolytic activity. It increases the endogenous fibrinolytic activity by promoting the cellular activator of plasminogen from endothelial cells and by decreasing the concentration of its inhibitors. In this study we evaluated a total of 223 patients for a mean period of 43 days for the following vascular conditions: (a) superficial venous thrombosis; (b) prophylaxis against deep venous thrombosis; (c) peripheral vascular disease (ischaemic foot and intermittent claudication; (d) prophylaxis against TIAs in patients with carotid plaques determining embolization; (e) treatment of venous ulcerations determined by chronic venous incompetence; (f) patients with Raynaud's phenomenon and disease. The tolerability observed was good. No side effects were observed even in more prolonged treatments. The overall efficacy was good for all groups especially in comparison with other treatment already in use for these vascular conditions. In conclusion defibrotide is a particularly useful drug in these vascular diseases and can be used both for acute and chronic treatments.
去纤苷是一种具有抗血栓形成和促纤溶活性的新化合物。它通过促进内皮细胞纤溶酶原的细胞激活剂以及降低其抑制剂的浓度来增加内源性纤溶活性。在本研究中，我们总共评估了223例患者，平均为期43天，涉及以下血管疾病：（a）浅静脉血栓形成；（b）预防深静脉血栓形成；（c）周围血管疾病（缺血性足和间歇性跛行）；（d）预防有颈动脉斑块且有栓塞风险的患者发生短暂性脑缺血发作（TIA）；（e）治疗由慢性静脉功能不全引起的静脉溃疡；（f）雷诺现象和雷诺病患者。观察到的耐受性良好。即使在更长时间的治疗中也未观察到副作用。总体疗效对所有组都很好，尤其是与这些血管疾病已在使用的其他治疗方法相比。总之，去纤苷在这些血管疾病中是一种特别有用的药物，可用于急性和慢性治疗。
